Asenapine induces differential regional effects on serotonin receptor subtypes

Journal of Psychopharmacology

Volumn 24, Issue 3, 2010, Pages 341-348

  Tarazi, F I ^a,b   Moran Gates, T ^a   Wong, E H F ^c   Henry, B ^d   Shahid, M ^d  

^a General Hospital   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PFIZER INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asenapine; Caudate putamen; Frontal cortex; Hippocampus; Serotonin receptor

Indexed keywords

ASENAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; ENTORHINAL CORTEX; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAT; ANIMAL; BRAIN; DOSE RESPONSE; IN VITRO STUDY; METABOLISM; RADIOASSAY; SPRAGUE DAWLEY RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN;

EID: 77953076000     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108095704     Document Type: Article

References (51)

1. Baldessarini, RJ, Tarazi, FI (2005) Pharmacotherapy of psychosis and mania. In: Brunton, LL, Lazo, JS, Parker, KL (eds.), Goodman. and Oilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, pp. 461-500.
2. Benes, FM, Berretta, S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25: 1-27.
3. Bleich, A, Brown, SL, Kahn, R, van Praag, HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297-315.
4. Burnet, PW, Chen, CP, McGowan, S, Franklin, M, Harrison, PJ (1996) The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73: 531-540.
5. De Boer, T, Berendsen, H, Broekkamp, CLE, Vrijmoed-de Vries, MC, Vos, RME, Tonnaer, JA, et al (1.993) Org-5222. Drugs Future 18: 1117-1123.
6. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831-10843.
7. Florijn, WJ, Tarazi, FI, Creese, I (1997) Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther 250: 561-569.
8. Frånberg, O, Wiker, C, Marcus, MM, Konradsson, A, Jardemark, K, Schilström, B, et al. (2008) Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 196: 417-429. (Pubitemid 351200428)
9. Francis, PT, Pangalos, MN, Pearson, RC, Middlemiss, DN, Stratmann, GC, Bowen, DM (1992) 5-HydroxytryptaminelA but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 261: 1273-1281.
10. Gilman, AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56: 615-649.
11. Greene, WH (2000) Econometric Analysis, fourth ed. Upper Saddle River, NJ: Prentice Hall, pp 462-465.
12. Gurevich, EV, Joyce, JN (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42: 529-545.
13. 1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 112: S35-S39.
14. Hoyer, D, Clarke, DE, Fozard, JR, Hartig, PR, Martin, GR, Mylecharane, EJ, et al. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46: 157-203. (Pubitemid 24185150)
15. Huang, M, Li, Z, Dai, J, Shahid, M, Wong, EF, Meltzer, HY (2008) Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology (Epub ahead of print, April 16).
16. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
17. Jarskog, LF, Miyamoto, S, Lieberman, JA (2007) Schizophrenia: new pathological insights and therapies. Annu Rev Med 58: 49-61. (Pubitemid 46706500)
18. Joyce, JN, Shane, A, Lexow, N, Winokur, A, Casanova, MF, Kleinman, JE (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8: 315-336. (Pubitemid 23162958)
19. Kapur, S, Agid, O, Mizrahi, R, Li, M (2006) How antipsychotics work-from receptors to reality. NeuroRx 3: 10-21. (Pubitemid 43276632)
20. 1c receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264: 1262-1267.
21. Laruelle, M, Abi-Dargham, A, Casanova, MF, Toti, R, Weinberger, DR, Kleinman, JE (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50: 810-818.
22. Leysen, JE, van Gompel, P, Gommeren, W, Laduron, PM (1987) Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone. Psychopharmacol Ser 3: 214-224.
23. Meltzer, HY (1999) The role of serotonin in antipsychotic drag action. Neuropsychopharmacology 21: 106S-115S.
24. Meltzer, HY, Nash, JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43: 587-604.
25. Meltzer, HY, Li, Z, Kaneda, Y, Ichikawa, J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159-1172.
26. 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35: 577-591.
27. 1A receptors. J Pharmacol Exp Ther 295: 853-861.
28. Mita, T, Hanada, S, Nishino, N, Kuno, T, Nakai, H, Yamadori, T, et al. (1986) Decreased serotonin. S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21: 1407-1414.
29. Neill, JC, Shahid, M, Wong, EHF, Idris, NF (2006) Comparison of the efficacy of asenapine, risperidone, and olanzapine to improve a reversal learning deficit in the rat. Schizophr Res 81: 105-106.
30. Newcomer, JW (2004) Metabolic risk during antipsychotic treatment. Clin Ther 26: 1936-1946.
31. O'Dell, SJ, La Hoste, GJ, Widmark, CB, Shapiro, RM, Potkin, SG, Marshall, JF (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146-153.
32. Ohuoha, DC, Hyde, TM, Kleinman, JE (1993) The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berl) 112: S5-S15.
33. Pazos, A, Palacios, JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346: 205-230.
34. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 12: 440-453.
35. Potkin, SG, Cohen, M, Panagides, J (2007) Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidonecontrolled trial, J Clin Psychiatry 68: 1492-1500.
36. 2C receptor antagonist properties of compounds. Eur J Pharmacol 388: 57-67.
37. 2c receptor. J Pharmacol Exp Ther 299: 83-89.
38. lC receptors. J Pharmacol Exp Ther 260: 1361-1365.
39. Roth, BL, Hanizavareh, SM, Blum, AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 174: 17-24.
40. Schotte, A, Janssen, PF, Gommeren, W, Luyten, WH, Van Gompel, P, Lesage, AS, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
41. Shahid, M, Walker, GB, Zorn, SH, Wong, EHF (2008) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (Epub ahead of print, February 28).
42. 1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39: 919-928.
43. 2C receptor is reduced in schizophrenia. Mol Psychiatry 6: 373-379.
44. 1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res 708: 209-214.
45. Tarazi, FI, Zhang, K, Baldessarini, RJ (2001) Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drag treatment. J Pharmacol Exp Ther 297: 711-717.
46. Tarazi, FI, Zhang, K, Baldessarini, RJ (2002) Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 161: 263-270.
47. Tarsy, D, Baldessarini, RJ, Tarazi, FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16: 23-45. (Pubitemid 34151336)
48. 2C serotonin receptors. Nature 374: 542-546.
49. 2 receptor subtypes. Mol Pharmacol 38: 594-598.
50. Winer, BJ, Brown, DR, Michels, KM (1991) Statistical Principles in Experimental Design, third ed. New York; McGraw Hill, pp. 165-166.
51. Wright, DE, Seroogy, KB, Lundgren, KH, Davis, BM, Jennes, L (1995) Comparative localization of serotonin 1A, 1C, and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 351: 357-373.